Differentiation of cardiomyocytes from human pluripotent stem cells using monolayer culture

Biomarker Insights

Volumn 10, Issue , 2015, Pages 71-76

  Batalov, Ivan ^a   Feinberg, Adam W ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Cardiomyocytes; Differentiation; Embryonic stem cells; Induced pluripotent stem cells; Review

Indexed keywords

6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ACTIVIN A; ALPHAVBETA5 INTEGRIN; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 4; CALSEQUESTRIN; DORSOMORPHIN; MATRIGEL; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR NANOG; VITRONECTIN; WNT PROTEIN;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL EXPANSION; CELL MATURATION; CELL POPULATION; CELL THERAPY; EMBRYOID BODY; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HUMAN; MONOLAYER CULTURE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

EID: 84930676346     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S20050     Document Type: Article

References (49)

1. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010study. Circulation. 2014;129(14):1483–92.
2. Laflamme MA, Murry CE. Heart regeneration. Nature. 2011;473(7347):326–35.
3. Antonio P, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):13.
4. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.
5. Place ES, Evans ND, Stevens MM. Complexity in biomaterials for tissue engi­neering. Nat Mater. 2009;8(6):457–70.
6. Feinberg AW. Engineered tissue grafts: opportunities and challenges in regen­erative medicine. Wiley Interdiscip Rev Syst Biol Med. 2012;4(2):207–20.
7. Egert U, Meyer T. Heart on a chip – extracellular multielectrode recordings from cardiac myocytes in vitro. In: Dhein S, Mohr F, Delmar M, eds. Practical Methods in Cardiovascular Research. Berlin: Springer; 2005:432–53.
8. Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip. 2013;13(18):3599–608.
9. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–72.
10. Wang G, McCain ML, Yang L, et al. Modeling the mitochondrial cardiomyo­pathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23.
11. Robertson C, Tran DD, George SC. Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells. 2013;31(5):829–37.
12. Feinberg AW, Ripplinger CM, van der Meer P, et al. Functional differences in engineered myocardium from embryonic stem cell-derived versus neonatal car­diomyocytes. Stem Cell Reports. 2013;1(5):387–96.
13. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–6.
14. McLaren A. Ethical and social considerations of stem cell research. Nature. 2001;414(6859):129–31.
15. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.
16. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451(7181):937–42.
17. Boheler KR. Differentiation of pluripotent embryonic stem cells into cardiomyo­cytes. Circ Res. 2002;91(3):189–201.
18. Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ. Differ­entiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012;111(3):344–58.
19. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19(8):998–1004.
20. Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, Wu JC. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One. 2010;5(2):e8975.
21. Guenther MG, Frampton GM, Soldner F, et al. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell. 2010;7(2):249–57.
22. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embry­onic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009;5(1):111–23.
23. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104(4):e30–41.
24. Lee YK, Ng KM, Lai WH, et al. Calcium homeostasis in human induced pluri­potent stem cell-derived cardiomyocytes. Stem Cell Rev. 2011;7(4):976–86.
25. Gupta MK, Illich DJ, Gaarz A, et al. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol. 2010;10:98.
26. Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013;112(3):523–33.
27. Xu H, Yi BA, Wu H, et al. Highly efficient derivation of ventricular cardiomyo­cytes from induced pluripotent stem cells with a distinct epigenetic signature. Cell Res. 2012;22(1):142–54.
28. Passier R, Oostwaard DW, Snapper J, et al. Increased cardiomyocyte differ­entiation from human embryonic stem cells in serum-free cultures. Stem Cells. 2005;23(6):772–80.
29. Graichen R, Xu X, Braam SR, et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentia­tion. 2008;76(4):357–70.
30. Mummery C, Ward-van Oostwaard D, Doevendans P, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003;107(21):2733–40.
31. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic effi­cacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a por­cine ischemic cardiomyopathy model. Circulation. 2012;126(11 suppl 1):S29–37.
32. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25(9):1015–24.
33. Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11(8):855–60.
34. Paige SL, Osugi T, Afanasiev OK, Pabon L, Reinecke H, Murry CE. Endoge­nous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One. 2010;5(6):e11134.
35. Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signal­ing. Proc Natl Acad Sci USA. 2012;109(27):E1848–57.
36. Lian X, Zhang J, Azarin SM, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc. 2013;8(1):162–75.
37. Cao N, Liang H, Huang J, et al. Highly efficient induction and long-term main­tenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cell Res. 2013;23(9):1119–32.
38. Kim HT, Lee KI, Kim DW, Hwang DY. An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells. Biomaterials. 2013;34(4):1041–50.
39. Delli Carri A, Onorati M, Castiglioni V, et al. Human pluripotent stem cell differentiation into authentic striatal projection neurons. Stem Cell Rev. 2013;9(4):461–74.
40. Ladewig J, Koch P, Brustle O. Auto-attraction of neural precursors and their neuronal progeny impairs neuronal migration. Nat Neurosci. 2014;17(1):24–6.
41. Viswanathan P, Gaskell T, Moens N, et al. Human pluripotent stem cells on artificial microenvironments: a high content perspective. Front Pharmacol. 2014;5:150.
42. Chang MY, Rhee YH, Yi SH, et al. Doxycycline enhances survival and self-renewal of human pluripotent stem cells. Stem Cell Reports. 2014;3(2):353–64.
43. Awe JP, Lee PC, Ramathal C, et al. Generation and characterization of trans­gene-free human induced pluripotent stem cells and conversion to putative clin­ical-grade status. Stem Cell Res Ther. 2013;4(4):87.
44. Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: qualitative effects on electrophysiological responses to drugs. Stem Cell Res. 2010;4(3):201–13.
45. Mihic A, Li J, Miyagi Y, et al. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. Bioma­terials. 2014;35(9):2798–808.
46. Nunes SS, Miklas JW, Radisic M. Maturation of stem cell-derived human heart tissue by mimicking fetal heart rate. Future Cardiol. 2013;9(6):751–4.
47. Yang X, Rodriguez M, Pabon L, et al. Tri-iodo-l-thyronine promotes the matu­ration of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296–304.
48. Liu J, Lieu DK, Siu CW, Fu J-D, Tse H-F, Li RA. Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyo­cytes by calsequestrin expression. Am J Physiol Cell Physiol. 2009;297(1):C152–9.
49. Kim C, Majdi M, Xia P, et al. Non-cardiomyocytes influence the electrophysi­ological maturation of human embryonic stem cell-derived cardiomyocytes dur­ing differentiation. Stem Cells Dev. 2010;19(6):783–95.